Circulating Cell-free miRNA Expression and its Association with Clinicopathologic Features in Inflammatory and Non-Inflammatory Breast Cancer

  • Hamdi, K (Laboratory of Genetics, Immunology and Human Pathology, Faculty of Sciences, University of Tunis El Manar) ;
  • Blancato, J (Lombardi Comprehensive Cancer Center, Georgetown University Medical Center) ;
  • Goerlitz, D (Lombardi Comprehensive Cancer Center, Georgetown University Medical Center) ;
  • Islam, MD (Lombardi Comprehensive Cancer Center, Georgetown University Medical Center) ;
  • Neili, B (Laboratory of Genetics, Immunology and Human Pathology, Faculty of Sciences, University of Tunis El Manar) ;
  • Abidi, A (Laboratory of Genetics, Immunology and Human Pathology, Faculty of Sciences, University of Tunis El Manar) ;
  • Gat, A (Laboratory of Genetics, Immunology and Human Pathology, Faculty of Sciences, University of Tunis El Manar) ;
  • Ayed, F Ben (Department of Medical Oncology, Hannibal International Clinic) ;
  • Chivi, S (Lombardi Comprehensive Cancer Center, Georgetown University Medical Center) ;
  • Loffredo, CA (Lombardi Comprehensive Cancer Center, Georgetown University Medical Center) ;
  • Jillson, I (Lombardi Comprehensive Cancer Center, Georgetown University Medical Center) ;
  • Elgaaied, A Benammar (Laboratory of Genetics, Immunology and Human Pathology, Faculty of Sciences, University of Tunis El Manar) ;
  • Marrakchi, R (Laboratory of Genetics, Immunology and Human Pathology, Faculty of Sciences, University of Tunis El Manar)
  • Published : 2016.06.01


Recent discovery showing the presence of microRNAs (miRNAs) in the circulation sparked interest in their use as potential biomarkers. Our previous studies showed the diagnostic potential of miR-451 as a serological marker for inflammatory breast cancer (IBC), miR-337-5p and miR-30b for non-inflammatory breast cancer (non-IBC). The aim of this study is to investigate the prognostic values of circulating miRNAs by comparing the amounts of 12 circulating miRNAs in the serum of IBC and non-IBC from Tunisian breast cancer patients, and by determinating whether correlated pairs of miRNAs could provide useful information in the diagnosis of IBC and non-IBC patients. TaqMan qPCR was performed to detect circulating expression of miRNAs in serum of 20 IBC, 20 non-IBC and 20 healthy controls. Nonparametric rank Spearman rho correlation coefficient was used to examine the prognostic value of miRNAs and to assess the correlation profile between miRNAs expression. Further, a large number of miRNAs were highly correlated (rho>0.5) in both patients groups and controls. Also, the correlations profiles were different between IBC, non-IBC and healthy controls indicating important changes in molecular pathways in cancer cells. Our results showed that miR-335 was significantly overexpressed in premenopausal non-IBC patients; miR-24 was significantly overexpressed in non-IBC postmenopausal patients. Patients with previous parity had higher serum of miR-342-5p levels than those without. Furthermore, patients with HER2+ IBC present lower serum levels of miR-15a than patients with HER2-disease. Together, these results underline the potential of miRNAs to function as diagnostic and prognostic markers for IBC and non-IBC, with links to the menopausal state, Her2 status and parity.


Supported by : American Association for the Advancement of Science (AAAS)


  1. Anfossi S, Giordano A, Gao H, et al (2014). High serum miR-19a levels are associated with inflammatory breast cancer and are predictive of favorable clinical outcome in patients with metastatic HER2+ inflammatory breast cancer. PLoS One, 9, 83113.
  2. Chen C, Ridzon DA, Broomer AJ, et al (2005). Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res, 33, e179.
  3. Chen X, Ba Y, Ma L, et al (2008). Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res, 18, 997-1006.
  4. Cittelly DM, Das PM, Salvo VA, et al (2010). Oncogenic HER2{Delta}16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors. Carcinogenesis, 31, 2049-57.
  5. Cortez MA, Bueso-Ramos C, Ferdin J, et al (2011). MicroRNAs in body fluids--the mix of hormones and biomarkers. Nat Rev Clin Oncol, 8, 467-77.
  6. Croce CM (2009). Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet, 10, 704-14.
  7. Dawood S, Cristofanilli M (2011). Inflammatory breast cancer: what progress have we made? Oncol, 25, 264-73.
  8. Dawood S, Merajver SD, Viens P, et al (2011). International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol, 22, 515-23.
  9. Fang Z, Tang J, Bai Y, et al (2015). Plasma levels of microRNA-24, microRNA-320a, and microRNA-423-5p are potential biomarkers for colorectal carcinoma. J Exp Clin Cancer Res, 34, 86.
  10. Gaziel-Sovran A, Segura MF, Di Micco R, et al (2011). miR- 30b/30d regulation of GalNAc transferases enhances invasion and immunosuppression during metastasis. Cancer Cell, 20, 104-18.
  11. Hagrass HA, Sharaf S, Pasha HF, et al (2015). Circulating microRNAs - a new horizon in molecular diagnosis of breast cancer. Genes Cancer, 6, 281-7.
  12. Hamdi K, Goerlitz D, Stambouli N, et al (2014). miRNAs in Sera of Tunisian patients discriminate between inflammatory breast cancer and non-inflammatory breast cancer. Springerplus, 3, 636.
  13. Hatse S, Brouwers B, Dalmasso B, et al (2014). Circulating MicroRNAs as easy-to-measure aging biomarkers in older breast cancer patients: correlation with chronological age but not with fitness/frailty status. PLoS One, 9, 110644.
  14. Hausler SF, Keller A, Chandran PA, et al (2010). Whole bloodderived miRNA profiles as potential new tools for ovarian cancer screening. Br J Cancer, 103, 693-700.
  15. Heneghan HM, Miller N, Kelly R, et al (2010). Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease. Oncologist, 15, 673-82.
  16. Huang Z, Huang D, Ni S, et al (2010). Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer, 127, 118-26.
  17. Kodahl AR, Lyng MB, Binder H, et al (2014). Novel circulating microRNA signature as a potential non-invasive multimarker test in ER-positive early-stage breast cancer: a case control study. Mol Oncol, 8, 874-83.
  18. Konishi H, Ichikawa D, Komatsu S, et al (2012). Detection of gastric cancer-associated microRNAs on microRNA microarray comparing pre-and post-operative plasma. Br J Cancer, 106, 740-7.
  19. Li X, Abdel-Mageed AB, Mondal D, et al (2013). MicroRNA expression profiles in differentiated thyroid cancer, a review. Int J Clin Exp Med, 6, 74-80.
  20. Liu YX, Long XD, Xi ZF, et al (2014). MicroRNA-24 modulates aflatoxin B1-related hepatocellular carcinoma prognosis and tumorigenesis. Biomed Res Int, 2014, 482926.
  21. Livak KJ, Schmittgen TD (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 25, 402-8.
  22. Lodes MJ, Caraballo M, Suciu D, et al (2009). Detection of cancer with serum miRNAs on an oligonucleotide microarray. PLoS One, 4, 6229.
  23. Lugli G, Cohen AM, Bennett DA, et al (2015). Plasma exosomal miRNAs in persons with and without alzheimer disease: altered expression and prospects for biomarkers. PLoS One, 10, 139233.
  24. Luo Q, Li X, Li J, et al (2013). MiR-15a is underexpressed and inhibits the cell cycle by targeting CCNE1 in breast cancer. Int J Oncol, 43, 1212-8.
  25. Mitchell PS, Parkin RK, Kroh EM, et al (2008). Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA, 105, 10513-8.
  26. Nassar FJ, El Sabban M, Zgheib NK, et al (2014). miRNA as potential biomarkers of breast cancer in the Lebanese population and in young women: a pilot study. PLoS One, 9, 107566.
  27. Palmero EI, de Campos SG, Campos M, et al (2011). Mechanisms and role of microRNA deregulation in cancer onset and progression. Genet Mol Biol, 34, 363-70.
  28. Roth C, Rack B, Muller V, et al (2010). Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res, 12, 90.
  29. Sayed D, Abdellatif M (2011). MicroRNAs in development and disease. Physiol Rev, 91, 827-87.
  30. Schwarzenbach H, Hoon DS, Pantel K (2011). Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer, 11, 426-37.
  31. Schwarzenbach H, Nishida N, Calin GA, et al (2014). Clinical relevance of circulating cell-free microRNAs in cancer. Nat Rev Clin Oncol, 11, 145-56.
  32. Shapira I, Oswald M, Lovecchio J, et al (2014). Circulating biomarkers for detection of ovarian cancer and predicting cancer outcomes. Br J Cancer, 110, 976-83.
  33. Shinden Y, Akiyoshi S, Ueo H, et al (2015). Diminished expression of MiR-15a is an independent prognostic marker for breast cancer cases. Anticancer Res, 35, 123-7.
  34. Simpson RJ, Lim JW, Moritz RL, et al (2009). Exosomes: proteomic insights and diagnostic potential. Expert Rev Proteomics, 6, 267-83.
  35. Tomimaru Y, Eguchi H, Nagano H, et al (2012). Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma. J Hepatol, 56, 167-75.
  36. Van der Auwera I, Limame R, van Dam P, et al (2010). Integrated miRNA and mRNA expression profiling of the inflammatory breast cancer subtype. Br J Cancer, 103, 532-41.
  37. Wang F, Zheng Z, Guo J, et al (2010). Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor. Gynecol Oncol, 119, 586-93.
  38. Wu C, Wang C, Guan X, et al (2014). Diagnostic and prognostic implications of a serum miRNA panel in oesophageal squamous cell carcinoma. PLoS One, 9, 92292.
  39. Wu Q, Lu Z, Li H, et al (2011). Next-generation sequencing of microRNAs for breast cancer detection. J Biomed Biotechnol, 2011, 597145.
  40. Wu Q, Wang C, Lu Z, et al (2012). Analysis of serum genomewide microRNAs for breast cancer detection. Clin Chim Acta, 413, 1058-65.
  41. Yamauchi H, Woodward WA, Valero V, et al (2012). Inflammatory breast cancer: what we know and what we need to learn. Oncologist, 17, 891-9.
  42. Yan LX, Huang XF, Shao Q, et al (2008). MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA, 14, 2348-60.
  43. Zeng X, Xiang J, Wu M, et al (2012). Circulating miR-17, miR-20a, miR-29c, and miR-223 combined as non-invasive biomarkers in nasopharyngeal carcinoma. PLoS One, 7, 46367.
  44. Zhang G, Liu Z, Cui G, et al (2014). MicroRNA-486-5p targeting PIM-1 suppresses cell proliferation in breast cancer cells. Tumour Biol, 35, 11137-45.
  45. Zhu W, Qin W, Atasoy U, et al (2009). Circulating microRNAs in breast cancer and healthy subjects. BMC Res Notes, 2, 89.

Cited by

  1. Biological features of inflammatory breast cancer in North Africa: burden and research priorities vol.7, pp.2, 2018,
  2. Expression signatures and roles of microRNAs in inflammatory breast cancer vol.19, pp.1, 2019,